

## DAFTAR PUSTAKA

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394–424.
2. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Ovarian cancer incidence and mortality. International Agency for Research on Cancer (IARC) Globocan. 2020. p. 5–6.
3. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: A review. *Cancer Biol Med.* 2017;14(1):9–32.
4. Adisasmita A, Maryani D, Dwipoyono B. Hubungan antara menyusui dengan risiko kanker ovarium. *Indones J Cancer.* 2016;10(3):93.
5. Hunn J, Rodriguez GC. Ovarian cancer: Etiology, risk factors, and epidemiology. *Clin Obstet Gynecol.* 2012;55(1):3–23.
6. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin.* 2018;68(4):284–96.
7. Lowe KA, Chia VM, Taylor A, O'Malley C, Kelsh M, Mohamed M, et al. An international assessment of ovarian cancer incidence and mortality. *Gynecol Oncol.* 2013;130(1):107–14.
8. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. *Gynecol Oncol.* 2013;129(1):258–64.
9. Globocan. Cancer incident in Indonesia. International Agency for Research on Cancer. 2020. p. 1–2.
10. Rambe IR, Asri A, Adrial A. Profil tumor ganas ovarium di Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Andalas periode Januari 2011 Sampai Desember 2012. *J Kesehat Andalas.* 2014;3(1):54–7.
11. Malik YA, Friadi A. ROMA and IOTA score comparison in predicting ovarian tumour malignancy. *Andalas Obstet Gynecol J.* 2020;70–6.
12. Dhitayoni IA, Budiman IN. Profil pasien kanker ovarium di Rumah Sakit Umum Pusat Sanglah Denpasar - Bali periode Juli 2013-2014. *J Medika Udayana.* 2017;37(6):578–80.
13. Fadhillah S, Oktora MZ, Pitra DAH. Profil tumor ovarium di RSI Siti Rahmah Padang tahun 2017-2018. *J Kesehat Sainatika Meditory.* 2021;4(2):130.
14. Lova NN. Pengaruh frekuensi pemberian kemoterapi terhadap status gizi berdasarkan indeks massa tubuh (IMT), total lymphocyte count (TLC) dan subjective global assessment pada pasien kanker saluran cerna. *Repository Brawijaya.* 2016;1–23.
15. Hadi S, Iskandar M. Hubungan anemia dan transfusi darah terhadap respons kemoradiasi pada karsinoma serviks uteri stadium IIB - IIIb. *Medica Hosp J Clin Med.* 2013;1(1):32–6.
16. Schrijvers D. Management of anemia in cancer patients: Transfusions. *Oncologist.* 2011;16(S3):12–8.
17. Xu H, Xu L, Page JH, Cannavale K, Sattayapiwat O, Rodriguez R, et al.

- Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010-2013. *Clin Epidemiol.* 2016;8:61–71.
18. Alghamdi AH, Niyaz RI, Al-Jifree H, Khan MA, Alsalmi L. Prevalence of anemia among gynecologic cancer patients who received chemotherapy, radiotherapy, or a combination of both at King Abdulaziz Medical City, Jeddah. *Cureus.* 2021;13(8).
  19. Buchrits S, Itzhaki O, Avni T, Raanani P, Gafter-Gvili A. Intravenous iron supplementation for the treatment of chemotherapy-induced anemia: A systematic review and meta-analysis of randomized controlled trials. *J Clin Med.* 2022;11(14).
  20. Hoque S, Chen BJ, Schoen MW, Carson KR, Keller J, Witherspoon BJ, et al. End of an era of administering erythropoiesis stimulating agents among veterans administration cancer patients with chemotherapy-induced anemia. *PLoS One.* 2020;15.
  21. Purwanto DAP, Mulatsih S, Triyono T. Faktor yang memengaruhi episode transfusi. *Indones J Of Cancer* 2017;11(2):49–54.
  22. Ludwig H, Apro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood TJ, et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anemia. *Support Care Cancer.* 2014;22(8):197–206.
  23. Hardiano R. Gambaran indeks massa tubuh pada pasien kanker yang menjalani kemoterapi. *JOM.* 2015. 2015;2(2).
  24. Razzaghdoust A, Mofid B, Peyghambarlou P. Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy. *Support Care Cancer.* 2020;28(1):155–61.
  25. Razzaghdoust A, Mofid B, Peyghambarlou P. Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy. *Support Care Cancer.* 2020;28(1):155–61.
  26. Chaumard N, Limat S, Villanueva C, Nerich V, Fagnoni P, Bazan F, et al. Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy. *Breast.* 2012;21(4):464–7.
  27. Napitupulu EM. Relationship between body mass index and hemoglobin levels in adolescents in Medan City, North Sumatra, Indonesia. *Int J Res Appl Sci Eng Technol.* 2022;10(5):2698–702.
  28. Enggardany R, Hendrati LY, Hairi NN. Relationship between body mass index (BMI) and anemia among adolescent Indonesian girls (analysis of the Indonesia Family Life Survey 5th data). *Amerta Nutr.* 2021;347–52.
  29. Gutierrez F, Gonzalez-de-la-Fuente GA, Nazco GJ, Oramas J, Batista N. Hematological toxicity of carboplatin for gynecological cancer according to body mass index. *Eur J Clin Pharmacol.* 2016;72(9):1083–9.
  30. Grabowski JP, Richter R, Rittmeister H, Chekerov R, Woopen H, Sehouli J. Impact of body mass index (BMI) on chemotherapy-associated toxicity in ovarian cancer patients. a pooled analysis of the North-Eastern German society of gynecological oncology (NOGGO) databank on 1,213 patients. *Anticancer Res.* 2018;38(10):5853–8.
  31. Gaitskell K, Green J, Pirie K, Reeves G, Beral V. Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type. *Int J*

- Cancer. 2016;138(5):1076–84
32. Prat J. Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features. *Virchows Arch*. 2012;460(3):237–49.
  33. Ogino S, Nishihara R, Vanderweele TJ, Wang M, Nishi A, Lochhead P, et al. Review article: the role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. *Epidemiology*. 2016. 602–611 p.
  34. Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. *J Clin Oncol*. 2012;30(21):2654–63.
  35. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. *JAMA Oncol*. 2016;2(4):482–90.
  36. Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel A V., et al. Ovarian cancer risk factors by histologic subtype: An analysis from the ovarian cancer cohort consortium. *J Clin Oncol*. 2016;34(24):2888–98.
  37. Bassuk SS, Manson JAE. Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. *Ann Epidemiol*. 2015;25(3):193–200.
  38. Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, DeFazio A, et al. Obesity and survival among women with ovarian cancer: Results from the ovarian cancer association consortium. *Br J Cancer*. 2015;113(5):817–26.
  39. Cannioto RA, Moysich KB. Epithelial ovarian cancer and recreational physical activity: a review of the epidemiological literature and implications for exercise prescription. *Gynecol Oncol*. 2015;137(3):559–73.
  40. Merritt MA, Poole EM, Hankinson SE, Willett WC, Tworoger SS. Dairy food and nutrient intake in different life periods in relation to risk of ovarian cancer. *Cancer Causes Control*. 2014;25(7):795–808.
  41. Koushik A, Wang M, Anderson KE, Tworoger SS, Clendenen TV, Eliassen AH, et al. Intake of vitamins A, C, and E and folate and the risk of ovarian cancer in a pooled analysis of 10 cohort studies. *Cancer Causes Control*. 2015;26(9):1315–27.
  42. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. *Lancet*. 2019;1240–53.
  43. Smith CG. A resident's perspective of ovarian cancer. *Diagnostics*. 2017;7(2).
  44. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. *J Ovarian Res*. 2019;12(1):1–9.
  45. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: An integrated review. *Semin Oncol Nurs*. 2019;35(2):151–6.
  46. Amjad MT, Chidharla A, Kasi A. Cancer chemotherapy. *StatPearls*. 2023. p. 1-2.
  47. Rosenberg JE, Hoffman-Censits J, Powles T, Balar AV, Necchi A, Dawson

- N, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. *Lancet*. 2016;5(7):1909–20.
48. Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. *BMJ*. 2020;371:1–20.
  49. Katzung BG. *Basic & clinical pharmacology* [e-book]. 14th ed. New York: McGraw-Hill Education; 2018 [cited 2023 Oct 20].
  50. Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. *Int J Mol Sci*. 2020;21(9).
  51. Vichaya EG, Chiu GS, Krukowski K, Lacourt TE, Kavelaars A, Dantzer R, et al. Mechanisms of chemotherapy-induced behavioral toxicities. *Front Neurosci*. 2015;9(4):1–17.
  52. Sisignano M, Baron R, Scholich K, Geisslinger G. Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. *Nat Publ Gr*. 2014;10(12):694–7.
  53. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary : Mechanisms and clinical impact. *Future Oncol*. 2016;12(20).
  54. Reck M, Robinson AG, Rodriguez-Abreu D, Hui R, Gottfried M, Peled N, et al. Updated Analysis of KEYNOTE-024 : Pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50 % or greater. *J Clin Onco*. 2019;37(7).
  55. Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. *Canc Immun Immunoth*. 2013;405–10.
  56. Waseem M, Kaushik P, Tabassum H, Parvez S. Role of mitochondrial mechanism in chemotherapy-induced peripheral neuropathy. *Curr Drug Metab*. 2018;47–54.
  57. Ferrara R, Imbimbo M, Malouf R, Calais F, Marchal C, Westeel V. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer (review). *Coch Data Syst Rev*. 2020;12(12).
  58. Oronsky B, Caroen S, Oronsky A, Dobalian VE, Oronsky N, Lybeck M, et al. Electrolyte disorders with platinum - based chemotherapy : Mechanisms, manifestations and management. *Canc Chemo Phar*. 2017;895–7.
  59. Stankovic JSK, Selakovic D, Mihailovic V. Antioxidant supplementation in the treatment of neurotoxicity induced by platinum-based chemotherapeutics— a Review. *Int J Mol Sci*. 2020;21(20):1–26.
  60. Xue Y, Gao S, Gou J, Yin T, He H, Wang Y, et al. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: Preclinical and clinical studies and mechanism of action. *Expert Opin Drug Deliv*. 2021;18(2):187–203.
  61. Makovec T. Cisplatin and beyond : molecular mechanisms of action and drug resistance development in cancer chemotherapy. *Radiol Oncol*. 2019;53(2):148–8.
  62. Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and

- anti-tumor strategies. *Theranostics*. 2022;12(5).
63. Moreira-Pais A, Ferreira R, Gil R. Platinum-induced muscle wasting in cancer chemotherapy: mechanisms and potential targets for therapeutic intervention. *Life Sci*. 2018;1(9):1–9.
  64. Wheate NJ. The side effects of platinum-based chemotherapy drugs: A review for chemists. *Dalton Trans*. 2018;47(19).
  65. Bryer E, Henry D. Chemotherapy-induced anemia: Etiology, pathophysiology, and implications for contemporary practice. *Int J Clin Transfus Med*. 2018;Volume 6:21–31.
  66. Yang L, Xie HJ, Li YY, Wang XIA, Liu XXIN, Mai JIA. Molecular mechanisms of platinum - based chemotherapy resistance in ovarian cancer (review). *Oncol Rep*. 2022;47(4):82.
  67. Martin EC, Aarons L, Yates JWT. Designing more efficient preclinical experiments : A simulation study in chemotherapy-induced myelosuppression. *Toxicol Sci*. 2016;150(1):109–16.
  68. Park SH, Lee MJ, Park CJ, Jang S, Seo EJ, Im HJ, et al. Bone marrow recovery of hematopoietic stem cells and microenvironment after chemotherapy in childhood acute lymphoblastic leukemia : Consecutive observations according to chemotherapy schedule. *Pediatr Hematol Oncol*. 2019;36(4):1–14.
  69. Kamimura K, Matsumoto Y, Zhou Q, Moriyama M. Myelosuppression by chemotherapy in obese patients with gynecological cancers. *Cancer Chemother Pharmacol*. 2016;78(3):633-4.
  70. Madeddu C, Gramignano G, Astaro G, Demontis R, Sanna E, Atzeni V, et al. Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach. *Front Physiol*. 2018;9:1–20.
  71. Thapa B, Mahendrakar N, Ramphul K. Paraneoplastic syndromes. *StatPearls*. 2023. p. 1-2.
  72. Henry K, Med P, Bs MB, Frcpath F. Paraneoplastic syndromes: Definitions, classification, pathophysiology, and principals of treatment. *Semin Diagn Pathol*. 2019;36(4):204-210.
  73. Viau M, Renaud MC, Grégoire J, Sebastianelli A, Plante M. Gynecologic oncology paraneoplastic syndromes associated with gynecological cancers: A systematic review. *Gynecol Oncol*. 2017;146(3):661–71.
  74. Tolkovsky A, Kipervasser S, Fainmesser Y, Alcalay Y. A paraneoplastic syndrome misdiagnosed as ALS : What are the red flags? a case report and review of the literature. *J Neuroimmunol*. 2021;15(9):358.
  75. Chung C, Allen E UG. Paraneoplastic syndromes: A focus on pathophysiology and supportive care. *Am J Health*. 2022;79(22):1988-2000.
  76. Farma NA, Muhammad S, Asterina A. Hubungan usia, hemoglobin, dan indeks massa tubuh dengan perubahan ukuran tumor pada kemoterapi neoadjuvant kanker serviks stadium IB2 dan IIA2 di RSUP Dr. M. Djamil Padang. *J Ilmu Kesehat Indones*. 2021;2(1):62–9.
  77. Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. *J Clin*

- Oncol. 2019;37(15):1336–51.
78. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. *Blood*. 2019;133(1):40–50.
  79. Pasini E, Corsetti G, Romano C, Aquilani R, Scarabelli T, Chen-Scarabelli C, et al. Management of anaemia of chronic disease: Beyond iron-only supplementation. *Nutrients*. 2021;13(1):1–10
  80. Par'i HM, Wiyono S, Harjatmo TP. Penilaian status gizi: Bahan ajar gizi [e-book]. 1th ed. Jakarta: Kementerian Kesehatan RI; 2017 [cited 2023 Jul 28].
  81. Utami D, Setyarini GA. Faktor-faktor yang mempengaruhi indeks massa tubuh pada remaja usia 15-18 tahun di SMAN 14 Tangerang. *J Ilmu Kedokt dan Kesehat*. 2017;4(3):207–5.
  82. Cetin DC, Nasr G. Obesity in the elderly: More complicated than you think. *Cleve Clin J Med*. 2014;81(1):51–61.
  83. Girsang VI, Munthe R, Pribadi T. Pengaruh kejadian kecacingan terhadap kadar Hb dan indeks masa tubuh anak. *Holistik J Kesehat*. 2019;12(4):265–70.
  84. Fall T, Ingelsson E. Genome-wide association studies of obesity and metabolic syndrome. *Mol Cell Endocrinol*. 2014;382(1):740–57.
  85. Rahayuningtyas PS. Hubungan asupan gizi dengan indeks massa tubuh (IMT) dan kadar hemoglobin narapidana umum wanita semarang. *J Kesehat Masy*. 2018;6(4):224–37.
  86. Furkon LA. Ilmu gizi dan kesehatan. *J Chem Inf Model*. 2016;53(9):1689–99.
  87. Mahdalena N, Ariati A. Pengaruh aktivitas fisik dengan indeks massa tubuh pada mahasiswa fakultas kedokteran UISU angkatan 2017. *J Kedokt Ibnu Nafis*. 2021;10(2):188–94.
  88. Magdalena R, Budi DR, Widanita N, Syafei M, Listiandi AD. Hubungan antara aktivitas fisik dengan indeks massa tubuh pada remaja. *Sains Olahraga dan Pendidik Jasmani*. 2021;21(1):1–10.
  89. Siregar YS, Widyaningsih W, Syahrudin E. Indeks massa tubuh, persentase otot rangka dan albumin pada pasien kanker paru karsinoma bukan sel kecil sebelum dan setelah kemoterapi. *J Respirologi Indones*. 2016;36(2):73–82.
  90. Sukarno J, Marunduh R, Pangemanan DHC. Hubungan indeks massa tubuh dengan kadar hemoglobin pada remaja di Kecamatan Bolangitang Barat Kabupaten Bolaang Mongondow Utara. *JKK*. 2016;1(1):29–35.
  91. Jho YL, Ping MF, Natalia E. Indeks massa tubuh remaja putri pada kejadian anemia di Asrama Melanie Samarinda. *MNJ*. 2020;2(7):305.
  92. Yahya S, Khan R, Amin S, Fatima I, Qayyum Y. Iron deficiency anemia and its relation with junk food. *Pakistan J Med Heal Sci*. 2022;16(7):713–5.
  93. Acharya S, Patnaik M, Mishra S, Panigrahi A. Correlation of hemoglobin versus body mass index and body fat in young adult female medical students. *Natl J Physiol Pharm Pharmacol*. 2018;8(9):1371.
  94. Triyonate EM, Kartini A. Faktor determinan anemia pada wanita dewasa usia 23-35 tahun. *J Nutr Coll*. 2015;4(3):259–63.
  95. Pasalina PE, Jurnal YD, Ariadi A. Hubungan indeks massa tubuh dengan kejadian anemia pada wanita usia subur pranikah. *J Ilmu Keperawatan dan*

- Kebidanan. 2019;10(1):12.
96. Wahidiyat PA, Adnani NB. Transfusi rasional pada anak. *Sari Pediatr.* 2017;18(4):325.
  97. Arifiyani N, Purnami SW. Indeks prognostik pada pasien kanker serviks di RSUD dr. Soetomo Surabaya menggunakan model regresi cox extended. *J Inferensi.* 2020;3:37–46.
  98. Dahlan MS. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan [e-book]. 3rd ed. Jakarta: Salemba Medika; 2010. [cited 2023 Jul 27].
  99. Triarico S, Capozza MA, Mastrangelo S, Attinà G, Maurizi P, Ruggiero A. Gynecological cancer among adolescents and young adults (AYA). *Ann Transl Med.* 2020;8(6):397.
  100. Wu Y, Qi Y, Yang J, Chen R, Li Q, Yang R, et al. Effect of adjuvant chemotherapy on the survival outcomes of elderly breast cancer: A retrospective cohort study based on SEER database. 2022;354–64.
  101. Abbema DL, Akker M, Janssen-Heijnen ML, Berkmortel F, Hoeben A, Vos-Geelen J, et al. Patient- and tumor-related predictors of chemotherapy intolerance in older patients with cancer: A systematic review. *J Geriatr Oncol.* 2018;10(1):31–41.
  102. Mallen A, Todd S, Robertson SE, Kim J, Sehovic M, Wenham RM, et al. Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer. *Gynecol Oncol.* 2021;161(3):693–9.
  103. Dion L, Mimoun C, Timoh KN, Bendifallah S, Bricou A, Collinet P, et al. Ovarian cancer in the elderly: Time to move towards a more logical approach to improve prognosis — a study from the FRANCOGYN group. *J Clin Med.* 2020;9(5).
  104. Harper EI, Hilliard TS, Sheedy EF, Carey P, Siroky MD, Yang J, et al. Another wrinkle with age: Aged collagen and intraperitoneal metastasis of ovarian cancer. 2023;3(2):116–29.
  105. Hua X, Zhu Q wei, Zhang Y nuan, Cao L. The prognostic significance of human ovarian aging-related signature in breast cancer after surgery: A multicohort study. *Front Immunol.* 2023;7(3):14.
  106. Ramirez J, Paris E, Basu S, Barua A. Age-associated molecular changes may predispose the ovary to malignant transformation leading to ovarian cancer (OVCA). *Cancer Res.* 2023;18(1):83.
  107. Martin L, Muscaritoli M, Bourdel-Marchasson I, Kubrak C, Laird B, Gagnon B, et al. Diagnostic criteria for cancer cachexia: Reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis. *J Cach Sarco Muscl.* 2021;12(5):1189-202.
  108. Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. *Nutrition.* 2019;28(6):67–68.
  109. Alici Y, Saltz V. Weight and appetite loss in cancer. *Psycho-Oncology.* 2021;26(1):298–302.
  110. Li X, Ding Y, Liu Y, Yang M. Differences between complex epithelial

- neoplasms of the ovary and high-grade serous ovarian cancer: A retrospective observational cohort study. *J Ovarian Res.* 2022;1(12):1–17.
111. Deng Y, Tan Y, Zhou D, Bai Y, Huang W, Zhong C, et al. Single-cell RNA-sequencing atlas reveals the tumor microenvironment of metastatic high-grade serous ovarian carcinoma. *Front Immunol.* 2022;13(7):1–17.
  112. Wilczyński J, Paradowska E, Wilczyński M. High-grade serous ovarian cancer — a risk factor puzzle and screening fugitive. *Biomedicines.* 2024;19(1):229.
  113. Tate S, Nishikimi K, Matsuoka A, Otsuka S, Shozu M. Safety and efficacy of weekly paclitaxel and cisplatin chemotherapy for ovarian cancer patients with hypersensitivity to carboplatin. *Cancers.* 2021;5(2):640.
  114. Falandry C, Rousseau F, Mouret-Reynier MA, Tinquaut F, Lorusso D, Herrstedt J, et al. Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: A GINECO/GCIG randomized. *JAMA Oncol.* 2021;7(6):853-861.
  115. Zhang H, Zhang Y. Olaparib and paclitaxel in combination with carboplatin in treatment of ovarian cancer : Influence on disease control. *Am J Transl Res.* 2022;14(1):468–75.
  116. Lampert EJ, Rose PG, Yao M, DeBernando R, Vargas RJ, Michener CM, et al. Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancer. *Int J Gynecol Canc.* 2023;33(7):1090-98.
  117. Wang H, Fan L, Wu X, Han Y. Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer. *BMC Womens Health.* 2022;22(1):1–9.
  118. Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, et al. Cancer- and chemotherapy-induced anemia. *J Natl Compr Cancer Netw.* 2012;10(5):628–53.
  119. Ramli NA, Ibrahım S, Ismail AAC, Hussin H. Incidence of anemia and red blood cell (RBC) transfusion requirement in breast cancer. *Casp J Int Med.* 2023;14(2):237–48.
  120. Cheng Y, Wu R, Cheng M, Du J, Hu X, Yu L, et al. Carboplatin-induced hematotoxicity among patients with non-small cell lung cancer : Analysis on clinical adverse events and drug-gene interactions. 2017;8(19):3228–36.
  121. Indhumathi P, Priya ES. Incidence and management of treatment-related side effects for patients receiving platinum therapy in an outpatient oncology clinic. *Asian J Pharm Clin Res.* 2017;10(8):18–21.
  122. Shah MJ, Patil VM, Noronha V, Menon NS, Singh AC, Jobanputra KN, et al. Impact of pre-treatment anemia on survival in locally advanced head neck squamous cell carcinomas treated with radiation with or without concurrent chemotherapy. *Journal of Clinical.* 2023;17(6):41.
  123. Palapinyo S, Klaewsongkram J, Sriuranpong V, Areepium N. Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients : A 5-year retrospective study. *Pharm Pract.* 2022;20(2):1–8.
  124. Öhlinger T, Müllner EW, Fritz M, Werning M, Baron-Stefaniak J, Jungbauer C, et al. Storage of packed red blood cells impairs an inherent coagulation

- property of erythrocytes. *Front Physiol.* 2022;25(11):1–11.
125. Münch F, Purbojo A, Wenzel F, Kohl M, Dittrich S, Rauh M, et al. Improved quality of stored packed red blood cells by mechanical rinsing. *Anaesthesiologie.* 2022;71(11):882–92.
  126. D’Avella C, Devarajan K, Edelman M, Geynisman D. The effect of packed red blood cell transfusions on the clinical efficacy of immunotherapy. *J For Immun Therap Canc.* 2020;8(3).
  127. Qin Y, Melse-Boonstra A, Pan X, Yuan B, Dai Y, Zhao J, et al. Anemia in relation to body mass index and waist circumference among chinese women. *Nutr J.* 2013;12(1):1.
  128. Kamruzzaman M. Is BMI associated with anemia and hemoglobin level of women and children in Bangladesh: A study with multiple statistical approaches. *PLoS One.* 2021;16(10):1–18.
  129. Dandavate N, Gadkari N, Rajbhoj A, Patil M, Gaikwad N, Bankar A. Study of anemia in non-luminal solid tumors. *Int J Advan Med.* 2023;10(7):563–8.
  130. Chatterjee D, Roy S, Hazra A, Dasgupta P, Ganguly S, Das AK. Variation of adverse drug reaction profile of platinum-based chemotherapy with body mass index in patients with solid tumors: An observational study. *Indian J Pharmacol.* 2014;46(2).
  131. Muthanna FMS, Karuppanan M, Abdulrahman E, Uitrakul S, Rasool BAH, Mohammed AH. Prevalence and associated factors of anemia among breast cancer patients undergoing chemotherapy: A prospective study. *Adv Pharmac Pharm Sci.* 2022;14(4).
  132. Camaschella C. Blood Reviews New insights into iron deficiency and iron deficiency anemia. *Blood Rev.* 2017;31(4):225–33.
  133. Sakaeva DD. Anemia and iron deficiency in cancer patients: The role of intravenous iron supplements (a literature review). *J of Modern Oncol.* 2022;486-76.
  134. Steinmeyer Z, Gérard S, Filleron T, Lozano S, Brechemier D, Mourey L, et al. Low lean mass and chemotherapy toxicity risk in the elderly: The fraction study protocol. 2019;27(12):1–8.
  135. Granfortuna J, Shoffner K, DePasquale SE, Badre S, Bohac C, Brandao CDO. Transfusion practice patterns in patients with anemia receiving myelosuppressive chemotherapy for nonmyeloid cancer: Results from a prospective observational study. *Supp Care Canc.* 2018;26(6):2031–38.
  136. Kojta I, Chacinska M, Blachnio-Zabielska A. Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance. *Nutrients.* 2020;12(5).
  137. Kanuri G, Sawhney R, Varghese J, Britto M, Shet A. Iron deficiency anemia coexists with cancer related anemia and adversely impacts quality of life. *PLoS One.* 2016;11(9):1–11.